| Active substance | selinexor |
| Holder | Karyopharm |
| Status | Running |
| Indication | Adult patients with relapsed or refractory multiple myeloma (RRMM), who have have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 10/08/2022 |